Prothena (PRTA) News Today

Bank of America reduced their price objective on Prothena from $33.00 to $31.00 and set a "neutral" rating for the company in a research report on Tuesday.

HC Wainwright reaffirmed a "buy" rating and set a $84.00 price objective on shares of Prothena in a research report on Tuesday.

Systematic Financial Management LP lifted its position in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) by 25.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 193,763 shares of the bio

Profund Advisors LLC cut its holdings in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) by 61.4% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 18,073 shares of the biotechnology company's stock after selling 28,805 sha

Armistice Capital LLC raised its holdings in Prothena Co. plc (NASDAQ:PRTA - Free Report) by 42.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 1,560,000 shares of the biotechnology company's stock after acquiring an additional 464,000 shares during the p

Shares of Prothena Co. plc (NASDAQ:PRTA - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seven ratings firms that are covering the company, MarketBeat reports. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. T

Federated Hermes Inc. bought a new stake in Prothena Co. plc (NASDAQ:PRTA - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 43,861 shares of the biotechnology company's stock, valued at approximately $905,000. Fed

Prothena (NASDAQ:PRTA) Shares Up 7.4%

Prothena Co. plc (NASDAQ:PRTA - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seven ratings firms that are covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on

Prothena (NASDAQ:PRTA) Stock Price Passes Below 200 Day Moving Average of $23.08

SG Americas Securities LLC lifted its holdings in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) by 226.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 54,572 shares of the biotechnology company's

Oppenheimer lowered their price target on shares of Prothena from $66.00 to $62.00 and set an "outperform" rating for the company in a report on Wednesday.

StockNews.com raised shares of Prothena from a "sell" rating to a "hold" rating in a research report on Monday.

Prothena (NASDAQ:PRTA - Get Free Report) announced its quarterly earnings data on Thursday. The biotechnology company reported $1.22 earnings per share for the quarter, beating analysts' consensus estimates of ($1.01) by $2.23. Prothena had a negative return on equity of 30.48% and a negative net margin of 193.17%. The company had revenue of $132.01 million for the quarter, compared to analyst estimates of $10.73 million. During the same quarter last year, the firm posted ($1.03) EPS. The firm's revenue for the quarter was up 3184.7% on a year-over-year basis.

Vanguard Group Inc. lifted its position in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) by 5.1% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,125,283 shares of the biotechnology company's

Royal Bank of Canada decreased their target price on Prothena from $28.00 to $24.00 and set a "sector perform" rating for the company in a research note on Friday.

Prothena (NASDAQ:PRTA) Shares Gap Up on Strong Earnings

Shares of Prothena Co. plc (NASDAQ:PRTA - Get Free Report) have received a consensus rating of "Moderate Buy" from the seven analysts that are currently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and five have given a buy recommend

Prothena (NASDAQ:PRTA) will be releasing earnings after the market closes on Thursday, August 8, Zacks reports.

Janus Henderson Group PLC decreased its stake in Prothena Co. plc (NASDAQ:PRTA - Free Report) by 35.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,309,590 shares of the biotechnology company's stock after selling

Price T Rowe Associates Inc. MD cut its position in Prothena Co. plc (NASDAQ:PRTA - Free Report) by 0.8% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,201,771 shares of the biotechn

Prothena Co. plc (NASDAQ:PRTA - Free Report) - Analysts at Zacks Research raised their Q2 2025 earnings per share estimates for shares of Prothena in a research note issued on Tuesday, July 23rd. Zacks Research analyst E. Bagri now anticipates that the biotechnology company will earn ($1.48) per

SG Americas Securities LLC trimmed its holdings in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) by 87.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,720 shares of the biotechnology company's stock a

Prothena Co. plc (NASDAQ:PRTA - Get Free Report) was the recipient of a significant decline in short interest in June. As of June 30th, there was short interest totalling 5,100,000 shares, a decline of 23.4% from the June 15th total of 6,660,000 shares. Based on an average trading volume of 527,700 shares, the days-to-cover ratio is currently 9.7 days.